Novartis AG (Basel, Switzerland) Tasigna Nilotinib Philadelphia chromosome-positive chronic myelogenous leukemia Phase III data showed that patients achieved significantly deeper molecular responses vs. Glivec (imatinib) 12/12/12 Onconova Therapeutics Inc. (Newtown, Pa.) Rigosertib Multikinase PI3K inhibitor Myelodysplastic syndromes and acute myeloid leukemia Phase I/II data showed that single-agent rigosertib was well tolerated and achieved effects that were in line with previous studies 12/12

Novartis AG, of Basel, Switzerland, said data published in The Lancet showed that patients on mTOR inhibitor Afinitor (everolimus) tablets with noncancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex experienced a significant reduction in tumor size and the absence of tumor progression

To make its case for requiring an adcom evaluation, Teva mentioned safety concerns that cropped up postmarket for other MS drugs, including Biogen's Tysabri (nataluzimab) and Novartis AG's Gilenya (fingolimod

The study tested multiple ascending doses of Somatoprim in healthy male volunteers, administered alone and in combination with Sandostatin (octreotide, Novartis AG

The study tested multiple ascending doses of Somatoprim in healthy male volunteers, administered alone and in combination with Sandostatin (octreotide, Novartis AG

Novartis AG, for instance, purchased a 19.9 percent equity stake in Alnylam Pharmaceuticals Inc

Biotech Products Approved in 2013 | Biotech Products Approved 1982-2012 BIOTECH PRODUCTS 2013 Company Product Marketer Indication (U.S. Approval Date; Month/Day) Theravance Inc. Breo Ellipta GlaxoSmithKline plc Chronic obstructive pulmonary disease (5/13) Genentech Inc. Actemra Genentech Inc. Polyarticular juvenile idiopathic arthritis (5/1) Raptor Pharmaceutical Corp. Procysbi Raptor Pharmaceutical Corp. Nephropathic cystinosis (5/1) Sucampo Pharmaceuticals

Boehringer Ingelheim GmbH Target validation deal for OBT to further validate potential targets from its OGAP database of human proteins OBT is getting an up-front payment and research funding and could receive milestones, as well as royalties Oxford BioMedica plc Novartis AG Deal to manufacture clinical grade material using Oxford's LentiVector gene delivery technology and to provide certain process development services Oxford will manufacture several batches of a lentiviral vector

Novartis AG (Basel, Switzerland) ND Expanded partnership to include Ylanthia and Slonomics technologies The two companies have agreed to cross-license future improvements, and have waived existing co-development options 11/8/12 II

Novartis AG; Basel, Switzerland) $43 Dendreon sold its immunotherapy manufacturing facility in Morris Plains, N.J., to Novartis Novartis paid $43M in cash 12/21/12 Evotec AG (Hamburg, Germany) Janssen Pharmaceuticals Inc. $175 Partnership for Evotec's NMDA antagonist portfolio Deal is worth a potential $75M up to launch, plus milestones payable on further products and/or indications, and $100M in commercial milestones 12/18/12 Genmab A/S (Copenhagen, Denmark) Kyowa Hakko Kirin Co

Novartis AG, of Basel, Switzerland, said results of two Phase III trials of an investigational compound, ACZ885, for systematic juvenile idiopathic arthritis (SJIA), appeared in the New England Journal of Medicine

Novartis AG, of Basel, Switzerland, said results of two Phase III trials of an investigational compound, ACZ885, for systematic juvenile idiopathic arthritis (SJIA), appeared in the New England Journal of Medicine

Dendreon Corp., of Seattle, said it sold its immunotherapy manufacturing facility in Morris Plains, N.J., to Novartis Pharmaceuticals Corp., a unit of Basel, Switzerland-based Novartis AG, for $43 million in cash...Trovagene Inc., of San Diego, said it granted Genoptix Inc., a unit of Basel, Switzerland-based Novartis AG, a worldwide, nonexclusive license to incorporate nucleophosmin protein, or NPM1, into research and clinical testing services for acute myelogenous leukemia

Vanda also has an FDA-approved product, Fanapt (iloperidone) for schizophrenia, marketed by Novartis AG

Under Intercell's deal for the Pseudomonas vaccine with Novartis AG, it is entitled either to receive royalties and potential development milestones of €120 million, or to co-develop the product, in which case it will take a share of the profits

DuoBodies, the subject of alliances with Novartis AG, Johnson & Johnson and one other unnamed big pharma company, are generated by exploiting a natural Fab-arm exchange process that occurs between IgG4 antibodies in vivo

Novartis AG, of Basel, Switzerland, said the FDA approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative

The proposed order required Watson and Actavis to sell the rights and assets to 18 drugs to Sandoz International GmbH, a unit of Basel, Switzerland-based Novartis AG, and to Par Pharmaceuticals Inc., of Woodcliff Lake, N.J., and to relinquish the manufacturing and marketing rights to three other drugs

Under Intercell's deal for the Pseudomonas vaccine with Novartis AG, it is entitled either to receive royalties and potential development milestones of €120 million, or to co-develop the product, in which case it will take a share of the profits